• 1
    Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol. 2005; 11: 23712384.
  • 2
    Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci. 2007; 52: 20152021.
  • 3
    Kruidenier L, Verspaget HW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease—radicals or ridiculous? Aliment Pharmacol Ther. 2002; 16: 19972015.
  • 4
    Mera K, Anraku M, Kitamura K, et al. The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun. 2005; 334: 13221328.
  • 5
    Witko-Sarsat V, Friedlander M, Khoa TN, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immun. 1998; 161: 25242532.
  • 6
    Kalousova M, Zima T, Tesar V, et al. Advanced glycoxidation end products in chronic diseases—clinical chemistry and genetic background. Mutat Res. 2005; 579: 3746.
  • 7
    Witko-Sarsat V, Gausson V, Nguyen A-T, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int. 2003; 64: 8291.
  • 8
    Peng K, Wu X, Zhao H, et al. Advanced oxidation protein products induce monocyte chemoattractant protein-1 expression via p38 mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Chin Med J. 2006; 119: 10881093.
  • 9
    Baskol G, Demir H, Baskol M, et al. Investigation of protein oxidation and lipid peroxidation in patients with rheumatoid arthritis. Cell Biochem Funct. 2006; 24: 307311.
  • 10
    Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relation with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2007; 77: 188192.
  • 11
    Tesarova P, Kalousova M, Soukupova J, et al. Carbonyl and oxidative stress in patients with breast cancer—is there a relation to the stage of the disease? Neoplasma. 2007; 54: 219224.
  • 12
    Kosova F, Cetin B, Akinci M, et al. Advanced oxidation protein products, ferrous oxidation in xylenol orange, malondialdehyde levels in thyroid cancer. Ann Surg Oncol. 2007; 14: 26162620.
  • 13
    Wykretowicz A, Adamska K, Krauze T, et al. The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults. Free Radic Res. 2007; 41: 645649.
  • 14
    Selmeci L, Seres L, Antal M, et al. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clin Chem Lab Med. 2005; 43: 294297.
  • 15
    Rentsch M, Beham A, Schlitt HJ, Jauch KW. Crohn's Disease Activity Index and Vienna Classification—is it worthwhile to calculate before surgery? Dig Surg. 2006; 23: 241249.
  • 16
    Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007; 133: 42332.
  • 17
    Matteucci E, Biasci E, Giampietro O. Advanced oxidation protein products in plasma: stability during storage and correlation with other clinical characteristics. Acta Diabetol. 2001; 38: 187189.
  • 18
    Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49: 13041313.
  • 19
    O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenerol. 2006; 20: 561573.
  • 20
    Rice-Evans CA, Diplock AT, Symons MCR. Techniques in free radical research, Amsterdam, The Netherlands: Elsevier Science Publishers BV; 1991.
  • 21
    Nourooz-Zadeh J, Tajaddini-Sarmadi J, Ling KLE, et al. Low-density lipoprotein is the major carrier of lipid hydroperoxides in plasma. Biochem J. 1996; 313: 781786.
  • 22
    Bartosz G. Druga twarz tlenu. Wolne rodniki w przyrodzie. 2nd ed. Warsaw, Poland: Wydawnictwo Naukowe PWN; 2004.
  • 23
    Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004; 159: 882890.
  • 24
    Valli A, Sulimasn ME, Meert N, et al. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta. 2007; 379: 8794.
  • 25
    McKenzie SJ, Baker MS, Buffinton GD, et al. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest. 1996; 98: 136141.
  • 26
    Khan WI, Motomura Y, Wang H, et al. Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol. 2006; 291: G803G811.
  • 27
    Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res. 2002; 51: 597604.
  • 28
    Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal failure. Circulation. 2002; 106: 22122217.
  • 29
    Selmeci L, Szekely M, Soos P, et al. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res. 2006; 40: 952958.
  • 30
    Gallardo JM, Prado-Uribe M, Amato D, et al. Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. Arch Med Res. 2007; 38: 3438.
  • 31
    Stange EF, Travis SPL, Vermeire S, et al. and for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55: i1i15.
  • 32
    Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426431.
  • 33
    Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the colesterol efflux capacity of serum using Fu5AH cell system. Metabolism Clin Exp. 2006; 55: 980988.
  • 34
    Keshavarzian A, Banan A, Farhadi A, et al. Increase in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut. 2003; 52: 720728.
  • 35
    Travis SPL, Stange EF, Lemann M, et al. and for the European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55: i16i35.
  • 36
    Tuzun A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem. 2002; 35: 569572.
  • 37
    Glemziene I, Kalibaitiene D, Kalpokaite Z, et al. The role of oxidative stress in digestive tract morbidity. Acta Medica Lituanica. 2001; 8: 1518.
  • 38
    Angriman I, Scarpa M, D'Incà R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007; 381: 6368.
  • 39
    Kruidenier L, Kuiper I, Lamers CB, et al. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol. 2003; 201: 2836.